Results of a Phase 1/2 Study of Lower Dose CPX-351 for Patients with Int-2 or High Risk IPSS Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia after Failure to Hypomethylating Agents

被引：0

作者：

Montalban-Bravo, Guillermo ^{[1
]}

Jabbour, Elias ^{[2
]}

Chien, Kelly S. ^{[1
]}

Borthakur, Gautam ^{[1
]}

Estrov, Zeev ^{[1
]}

Kadia, Tapan M. ^{[1
]}

Ravandi, Farhad ^{[1
]}

Pemmaraju, Naveen ^{[1
]}

Nogueras-Gonzalez, Graciela ^{[3
]}

Schneider, Heather ^{[4
]}

John, Rosmy ^{[4
]}

Meyer, Meghan Anne ^{[4
]}

Kantarjian, Hagop M. ^{[4
]}

Garcia-Manero, Guillermo ^{[2
]}

Dong, Xiao Qin

机构：

[1] Univ Texas MD Anderson Canc Ctr, Dept Leukemia, Houston, TX USA

[2] Univ Texas MD Anderson Canc Ctr, Houston, TX USA

[3] Univ Texas MD Anderson Canc Ctr, Biostat, Houston, TX USA

[4] Univ Texas MD Anderson Canc Ctr, Leukemia, Houston, TX USA

来源：

关键词：

D O I：

10.1182/blood-2023-178110

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页数：5